SCHEMBL5358993

SCHEMBL5358993

COCOC(CCNS(=O)(=O)c1ccsc1C(=O)OC)c1ccc(F)cc1

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 1/20 0.41
LMNA P02545 4/20 0.40
ALDH1A1 P00352 3/20 0.40
CYP1A2 P05177 1/20 0.40
CYP2D6 P10635 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
MAPT P10636 4/20 0.39
SMN1; SMN2 Q16637 4/20 0.39
EDNRA P25101 3/20 0.39
PKM P14618 1/20 0.38
RECQL P46063 1/20 0.37
PPARG P37231 1/20 0.36
PPARD Q03181 1/20 0.36
PPARA Q07869 1/20 0.36
POLB P06746 1/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
USP2 O75604 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5352377 0.92 SMN1; SMN2 (0.39) KCNH2LMNAALDH1A1CYP1A2CYP2D6
SCHEMBL5354260 0.85 KCNH2 (0.45) KCNH2LMNAALDH1A1CYP1A2CYP2D6
SCHEMBL5358765 0.82 SMN1; SMN2 (0.34) LMNAMAPTSMN1; SMN2USP2
SCHEMBL5358989 0.81 LMNA (0.44) KCNH2LMNAALDH1A1CYP1A2CYP2D6
SCHEMBL5354487 0.78 ALDH1A1 (0.54) KCNH2LMNAALDH1A1CYP1A2CYP2D6
SCHEMBL5352376 0.72 LMNA (0.38) LMNAALDH1A1CYP1A2CYP2D6CYP2C9
SCHEMBL12293577 0.71 MAPT (0.65) KCNH2LMNAALDH1A1CYP1A2CYP2D6
SCHEMBL19002774 0.71 EDNRA (0.45) KCNH2LMNAALDH1A1MAPTSMN1; SMN2
SCHEMBL21169275 0.70 EDNRA (0.43) KCNH2LMNACYP1A2MAPTEDNRA
SCHEMBL19002770 0.69 EDNRA (0.50) LMNAALDH1A1CYP1A2CYP2C19MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7217723-B2 Substituted benzothiophenes, e.g., 7Z)-7-hydroxyimino-4,5,6,7-tetrahydro-benzo[b]thiophene-3-sulfonic acid [2-(4-fluorophenyl)-2-hydroxyethyl]-methyl-amide; treating allergies such as atopic dermatitis, allergic coryza, bronchial asthma, hypersensitive pneumoniac and pulmonary aspergillosis. EISAI CO., LTD. (JP) 2007-05-15 US disclosed
US-20050227959-A1 Heterocyclic compound having oxime group EISAI CO., LTD. (JP) 2005-10-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050227959-A1 Heterocyclic compound having oxime group STAT6, HRH4, HRH2 KCNH2 1168/4885LMNA 4744/4885ALDH1A1 1391/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.